1. Home
  2. XBIT vs IPHA Comparison

XBIT vs IPHA Comparison

Compare XBIT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.16

Market Cap

66.8M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.88

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
IPHA
Founded
2005
1999
Country
United States
France
Employees
87
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.8M
165.3M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
XBIT
IPHA
Price
$2.16
$1.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
45.9K
33.6K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$1.18
52 Week High
$3.44
$2.71

Technical Indicators

Market Signals
Indicator
XBIT
IPHA
Relative Strength Index (RSI) 42.52 43.86
Support Level N/A $1.67
Resistance Level $2.46 $2.66
Average True Range (ATR) 0.05 0.11
MACD -0.00 -0.03
Stochastic Oscillator 23.53 18.24

Price Performance

Historical Comparison
XBIT
IPHA

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: